The Bulwark's recent piece by David Shaywitz poses a provocative question to healthcare executives: 'What are you willing to sacrifice for a much better American health care system?' The room fell silent, broken only by a quip about smoking. This anecdote captures a deeper truth mainstream coverage rarely confronts head-on. While the article rightly highlights that U.S. healthcare consumes 18% of GDP ($5.3 trillion annually) with uneven quality and calls for disruption over incremental tweaks, it stops short of naming the politically toxic trade-offs ordinary Americans and industry players fiercely resist.

Our analysis draws on comparative health systems research to go further. A landmark 2018 observational study in JAMA by Papanicolas, Woskie, and Jha (sample: spending and outcomes data from 10 high-income countries, no declared conflicts) found the U.S. spends nearly double per capita what peers like Germany or Australia do, yet achieves middling outcomes on amenable mortality. Administrative complexity, high prices, and overuse of low-value services drive much of the waste—yet proposals to address these collide with public attachments the original source underplays.

Mainstream reporting often frames reform as a question of expanding access or lowering drug prices. What it misses is the cultural and psychological barriers: Americans' deep attachment to unlimited provider choice, rapid access to specialists and high-tech interventions regardless of cost-effectiveness, and a fee-for-service model that rewards volume. A 2021 Commonwealth Fund Mirror, Mirror report (observational survey of ~20,000 adults across 11 countries, rigorous risk-adjustment but inherent limits of self-reported data) ranked the U.S. dead last in access, efficiency, and equity despite highest spending. Countries achieving better results use tools we resist: centralized price negotiation, global budgets, and explicit rationing based on comparative effectiveness.

Consider what genuine disruption requires. To cut $1.75 trillion annually as Shaywitz suggests (reaching ~12.5% of GDP), stakeholders must sacrifice:

1. Unlimited choice and minimal wait times. Single-payer or tightly regulated systems control costs partly through gatekeeping and queues for elective procedures. U.S. patients expect same-week specialist visits and MRI access without referral; evidence from OECD longitudinal data shows this convenience correlates with higher spending but not always better health-adjusted life expectancy.

2. Unfettered pharmaceutical pricing and direct-to-consumer advertising. Monopoly pricing funds innovation, yet a 2022 peer-reviewed analysis in Health Affairs (quasi-experimental study of drug launches pre/post-patent, n>300 compounds) suggests marginal innovation gains from U.S.-level prices are smaller than assumed, with much R&D focused on 'me-too' drugs. Public attachment to the latest cancer therapies—even those extending life by weeks at six-figure costs—blocks value-based frameworks.

3. Employer-sponsored insurance as the default. This tax-advantaged system (rooted in WWII wage controls) insulates many from true costs but fragments risk pools and perpetuates job-lock. Proposals like Medicare for All trigger visceral fear of losing 'what we have,' a pattern seen in the demise of the public option in 2009-2010 and repeated since.

The original coverage correctly notes everyone wants 'more money'—hospitals seek higher private insurer rates, pharma defends monopolies, insurers want bigger Medicare Advantage bonuses. Yet it under-analyzes how these demands reflect misaligned incentives no one wants to surrender. Peer-reviewed evidence consistently shows administrative waste (up to 25-30% of spending per some estimates from RAND Corporation observational modeling) stems from our fragmented multi-payer system. Switzerland and Germany achieve universal coverage with regulated private insurers but enforce community rating, standardized benefits, and aggressive price caps—sacrifices U.S. stakeholders avoid discussing.

Public polling reveals the attachment problem: Kaiser Family Foundation surveys show majorities support 'Medicare for All' in abstract but support plummets when told it might limit choice of doctors or hospitals. This isn't mere policy detail; it's a cultural belief that healthcare should be exempt from the resource constraints governing every other sector. As Ezekiel Emanuel has argued in NEJM perspective pieces, true reform demands accepting that 'more' is not always better—overtreatment causes harm via cascades of unnecessary care (supported by RCT evidence on low-value screening).

The season-of-sacrifice framing in the source is apt but incomplete without acknowledging Abrahamic traditions also emphasize communal welfare over individual maximization. Our healthcare exceptionalism—prioritizing individual autonomy and technological optimism—clashes with population health realities. Without honest debate on these attachments, 'disruption' remains executive jargon. Real improvement requires naming the sacred cows: the illusion of unlimited high-cost care without trade-offs, the resistance to government stewardship that works elsewhere, and the preference for familiar dysfunction over unfamiliar efficiency. Only then can we redirect even a fraction of that $4,500 per person annual excess toward genuine wellness, prevention, and equitable outcomes.